Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Phase II/III Trial of Ustekinumab to Treat Type 1 Diabetes (UST1D2)

NCT03941132 is registered in ClinicalTrials.gov with University of British Columbia as lead sponsor.

NCT NCT03941132
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03941132 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Phase II/III Trial of Ustekinumab to Treat Type 1 Diabetes (UST1D2)
Lead sponsor
University of British Columbia
Phase
Phase 2/3
Overall status
Active, not recruiting
Start date
January 4, 2021
Completion date
November 1, 2026
Enrollment
66 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

type 1 diabetes mellitus